The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Research Grant, 2020Assessing Target Engagement for Terazosin
Study Rationale:
Patients with Parkinson’s disease (PD) do not produce enough of a compound called ATP. If a person does not make enough ATP, the cells in the body can die. This is very important... -
Research Grant Supplement, 2020LIMP-2 as a Scaffolding Protein to Characterize PD-Associated GCase Variants
Promising Outcomes of Original Grant:
Our original grant focused on determining the structure of the complex formed by the Parkinson’s-associated protein beta-gluccocerebrosidase (GCase) and its... -
Therapeutic Pipeline Program, 2020Using Vestibular Stimulation to Improve Neurovascular Status in Parkinson’s Disease
Study Rationale:
Caloric vestibular stimulation activates the vestibular system, a sensory network with pathways spreading throughout the brain. The vestibular system is responsible for providing... -
Research Grant Supplement, 2020Measuring LRRK2-Mediated Rab Protein in Parkinson’s Disease
Study Rationale:
The discovery of LRRK2 (Leucine rich repeat kinase 2) recently as a gene that causes Parkinson’s disease has provided considerable insights into the development of both familial and... -
Research Grant Supplement, 2020Discovery of Selective PET Imaging Agents for Tauopathies and Alpha-Synuclein
Study Rationale:
The development of alpha-synuclein and tau imaging agents will be valuable for people with Parkinson’s disease and Frontal Temporal Dementia (FTD), as deposits of these proteins... -
Biosample Use Program, 2020Mass Spectrometric Analysis of Glucocerebrosidase Protein Levels and Spinal Fluid in People with Parkinson’s
Study Rationale:
Mutations in the glucocerebrosidase (GBA) gene are among the most important risk factors for developing Parkinson´s disease. GBA activity is reduced in cerebrospinal fluid (CSF) of...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.